CMS Rebate Shift & NICE Threshold

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel like a perfect storm of system pressures and methodological evolution.

MarcusExactly. We're looking at CMS's Medicaid rebate program modifications — which could fundamentally reshape manufacturer reporting and rebate calculations. Then ICER's expansion of early-phase scientific advice to include Phase I and II trials — a direct response to industry demand for earlier HEOR input. The FDA's draft guidance on real-world data for accelerated approvals in neurodegenerative diseases — emphasizing robust post-marketing studies. And NICE's consultation on increasing the cost-effectiveness threshold for highly specialized technologies from £50,000 to £100,000 per QALY.

SaraThat first one on CMS is particularly interesting to me — the budget impact implications of recalibrating rebates for high-cost drugs could ripple through Medicaid formularies in ways we haven't fully modeled yet.

MarcusAbsolutely. Let's get into it.

MarcusStarting with CMS: The proposed modifications to the Medicaid Drug Rebate Program focus on manufacturer reporting requirements and rebate calculations for high-cost drugs. The stated aim is increased transparency and alignment with the Inflation Reduction Act's price negotiation provisions. This isn't just administrative housekeeping — it's a structural shift in how rebates interact with manufacturer obligations.

SaraThat's one read — but I'd frame it slightly differently. What strikes me is the potential for unintended consequences on state-level budgets. If rebates become more complex to calculate, we might see more variability in rebate recovery rates, especially for ultra-orphan drugs where patient populations are sparse. The part that gives me pause is how this interacts with the IRA's negotiation timelines.

MarcusThat's fair, though I think manufacturers would see it as a clarifying step. The IRA provisions create new rebate calculation triggers, and CMS is trying to streamline that. But you're right about the operational complexity — we've seen similar rebate recalibrations in Europe lead to temporary market access disruptions while systems adapted.

SaraExactly, and from the payer side, the budget impact question here is one the field hasn't fully worked out. Will this reduce administrative burden or just shift the burden? The opportunity cost of implementing these changes could divert resources from other value-based initiatives.

MarcusThat connects to something I keep coming back to: how these rebate changes might influence future pricing strategies. If rebates become more predictable, sponsors might feel more confident in upfront pricing, but the flip side is that higher rebates could net out to lower effective prices, complicating value propositions.

SaraWhat's striking here is the timing too — with the first IRA price negotiations looming, this feels like CMS trying to shore up the rebate system's integrity before it faces new pressure. But I wonder if that's the full picture though — will this actually reduce the gaming we've seen with average manufacturer price calculations?

MarcusThat's a critical point. Historically, rebate recalibrations have sometimes led to new loopholes. The key will be how CMS enforces the new reporting requirements. If they can't audit effectively, the transparency gains might be theoretical.

SaraWhich brings us back to the budget impact. Even with perfect implementation, the transition costs could be significant for both payers and manufacturers. This is one of those stories where the details matter more than the headlines.

SaraShifting to ICER: Their expansion of early-phase scientific advice to include Phase I and II trials is a direct response to industry demand for earlier HEOR input. The program now offers real-time evidence generation support during development, which could de-risk late-stage failures. This feels like a necessary evolution given the increasing complexity of trial designs.

MarcusI'd push back slightly on that framing. While the expansion is significant, ICER's advice remains advisory — it doesn't replace regulatory pathways. What's interesting is how this could accelerate evidence generation, but the methodological rigor for Phase I/II data is still untested in HTA contexts. Will payers accept RWE from such early stages?

SaraThat's fair, though I think payers would see it differently. The budget impact angle is that earlier evidence generation could prevent costly late-stage rejections. If ICER can help sponsors design trials with HTA-relevant endpoints from the start, that reduces the risk of sunk costs for both industry and the system.

MarcusBut the part that gives me pause is the resource allocation. ICER is already stretched with their core assessment work. Can they deliver high-quality early-phase advice without compromising their primary remit? We've seen similar initiatives in Europe struggle with capacity constraints.

SaraRight, and from the payer side, the opportunity cost question is whether this diverts resources from evaluating drugs that are already approved. If ICER spends more time on early-phase advice, does that mean fewer full assessments? That could create access gaps for near-term innovations.

MarcusThat connects to something I keep coming back to: how this might change sponsor behavior. If companies get early ICER input, might they over-index on HTA considerations at the expense of clinical innovation? The tension between generating evidence and generating breakthroughs is real.

SaraWhat's striking here is the patient perspective too — earlier evidence generation could theoretically speed up access, but only if the evidence is robust enough to satisfy payers. This is one of those stories where the intention is good, but the execution will determine whether it creates value or just adds layers to development.

MarcusExactly. The proof will be in whether sponsors report meaningful changes to trial designs based on this advice. If it's just a checkbox exercise, we haven't really advanced the conversation.

MarcusNow to the FDA: Their draft guidance on using real-world data to support accelerated approvals for neurodegenerative diseases emphasizes the need for robust post-marketing studies. This signals a tightening of the evidentiary bar for these pathways, particularly given the high stakes in Alzheimer's and Parkinson's. It's a recognition that RWE can't be a substitute for confirmatory trials.

SaraThat's one read — I'd frame it slightly differently. What strikes me is the operational burden this places on sponsors. Neurodegenerative diseases have long natural histories and heterogeneous patient populations, making post-marketing studies incredibly expensive and logistically challenging. The part that gives me pause is how this interacts with the IRA's negotiation timeline — if confirmatory data takes years to generate, how do we ensure patients aren't left in limbo?

MarcusThat's a critical point. The FDA is essentially saying accelerated approvals are still conditional, but the guidance doesn't address the commercial viability of conducting those confirmatory studies. If sponsors can't recoup investment from a product that's under review for price negotiation, will they still pursue these pathways?

SaraExactly, and from the payer side, the budget impact question is whether this leads to more conditional approvals followed by market withdrawals. That creates uncertainty for formulary decisions and leaves patients without established treatments. The opportunity cost of managing these conditional approvals could strain system resources.

MarcusThat connects to something I keep coming back to: the tension between innovation access and evidence certainty. The FDA is right to demand robust evidence, but if the pathway becomes too burdensome, we might see fewer breakthroughs for these underserved populations. This is one of those stories where the patient perspective is paramount — but the system needs sustainable solutions.

SaraWhat's striking here is the global implications too. Other regulators will watch how this plays out in the US, and it could set a precedent for RWE use in accelerated approvals worldwide. But I wonder if that's the full picture though — will this guidance actually reduce the number of accelerated approvals, or just make them more evidence-based?

MarcusThe latter, I suspect. Sponsors will still pursue these pathways because the unmet need is so high, but they'll need to build stronger RWE strategies from the start. The key is whether FDA can provide clear expectations for what constitutes "robust" post-marketing data.

SaraFinally, NICE's consultation on increasing the cost-effectiveness threshold for highly specialized technologies from £50,000 to £100,000 per QALY is a significant shift. The stated rationale is to reflect innovation in ultra-orphan therapies, but it fundamentally challenges the £20,000-£30,000 threshold that's been the bedrock of UK value assessments for decades.

MarcusI'd push back slightly on that characterization. This isn't just about ultra-orphans — it's about highly specialized technologies broadly. The consultation explicitly mentions therapies with limited treatment alternatives and high unmet need. What's interesting is whether this signals a broader acceptance of higher thresholds for certain disease areas, not just rare diseases.

SaraThat's fair, though I think payers would see it as a necessary but dangerous precedent. The budget impact question is whether this opens the floodgates for higher prices across the board. If one disease area gets a higher threshold, why not others? The opportunity cost could be substantial for other innovations.

MarcusBut the part that gives me pause is the methodological inconsistency. How do you justify a £100,000 threshold for one therapy while maintaining £30,000 for another in the same system? It risks creating a two-tiered value assessment process that undermines the entire framework's credibility.

SaraExactly, and from the payer side, the equity implications are profound. If ultra-orphan therapies get preferential treatment, what about common diseases with high unmet need? This could exacerbate health inequalities by shifting resources toward rare conditions at the expense of broader populations.

MarcusThat connects to something I keep coming back to: how this might change sponsor behavior. Companies might now prioritize ultra-orphan development knowing the threshold is higher, potentially neglecting areas with larger patient populations but lower willingness-to-pay. The innovation ecosystem could become skewed toward niche products.

SaraWhat's striking here is the timing too — with the NHS under unprecedented financial pressure, this feels like a politically difficult consultation. But I wonder if that's the full picture though — will this actually improve access for ultra-orphan therapies, or just create new barriers through higher evidentiary expectations?

MarcusThe latter is more likely. If NICE raises the threshold but simultaneously demands more evidence, we might not see a net improvement in access. This is one of those stories where the intention is good, but the implementation will determine whether it helps patients or just adds complexity to value assessments.

SaraA lot to think about today. I'll be watching how CMS's rebate modifications interact with the IRA price negotiations — that could be the real test of whether this creates more transparency or just more complexity.

MarcusSame — and for me the thread running through today is the tension between system sustainability and innovation access. Every story we discussed comes back to that fundamental question of how we balance evidence rigor with patient needs.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.